These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26898434)

  • 1. The role of oncomirs in the pathogenesis and treatment of breast cancer.
    Hemmatzadeh M; Mohammadi H; Jadidi-Niaragh F; Asghari F; Yousefi M
    Biomed Pharmacother; 2016 Mar; 78():129-139. PubMed ID: 26898434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.
    Tahiri A; Leivonen SK; Lüders T; Steinfeld I; Ragle Aure M; Geisler J; Mäkelä R; Nord S; Riis ML; Yakhini Z; Kleivi Sahlberg K; Børresen-Dale AL; Perälä M; Bukholm IR; Kristensen VN
    Carcinogenesis; 2014 Jan; 35(1):76-85. PubMed ID: 24104550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor microRNAs: Targeted molecules and signaling pathways in breast cancer.
    Asghari F; Haghnavaz N; Baradaran B; Hemmatzadeh M; Kazemi T
    Biomed Pharmacother; 2016 Jul; 81():305-317. PubMed ID: 27261608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications.
    Otmani K; Rouas R; Lewalle P
    Front Immunol; 2022; 13():913951. PubMed ID: 36189271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer and microRNAs: therapeutic impact.
    Iorio MV; Casalini P; Piovan C; Braccioli L; Tagliabue E
    Breast; 2011 Oct; 20 Suppl 3():S63-70. PubMed ID: 22015296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and epigenomic cross-talks in the regulatory landscape of miRNAs in breast cancer.
    Samantarrai D; Dash S; Chhetri B; Mallick B
    Mol Cancer Res; 2013 Apr; 11(4):315-28. PubMed ID: 23360796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum.
    Sochor M; Basova P; Pesta M; Dusilkova N; Bartos J; Burda P; Pospisil V; Stopka T
    BMC Cancer; 2014 Jun; 14():448. PubMed ID: 24938880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.
    Liu B; Tian Y; Li F; Zhao Z; Jiang X; Zhai C; Han X; Zhang L
    Oncol Rep; 2016 Jun; 35(6):3178-84. PubMed ID: 27109339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The duality of oncomiR addiction in the maintenance and treatment of cancer.
    Cheng CJ; Slack FJ
    Cancer J; 2012; 18(3):232-7. PubMed ID: 22647359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OncomiRs: the discovery and progress of microRNAs in cancers.
    Cho WC
    Mol Cancer; 2007 Sep; 6():60. PubMed ID: 17894887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
    Luo Q; Li X; Li J; Kong X; Zhang J; Chen L; Huang Y; Fang L
    Int J Oncol; 2013 Oct; 43(4):1212-8. PubMed ID: 23900351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of microRNA-10b overexpression in breast cancer: a meta-analysis.
    Wang N; Chen P; Huang LP; Wang TZ
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.
    Peng F; Xiong L; Tang H; Peng C; Chen J
    Tumour Biol; 2016 Nov; 37(11):14463-14477. PubMed ID: 27644253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer.
    Bašová P; Pešta M; Sochor M; Stopka T
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 28994735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1.
    Zheng M; Sun X; Li Y; Zuo W
    Tumour Biol; 2016 Jun; 37(6):8189-96. PubMed ID: 26715279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (review).
    Zhang K; Zhang Y; Liu C; Xiong Y; Zhang J
    Int J Oncol; 2014 Sep; 45(3):950-8. PubMed ID: 24913679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer.
    O'Bryan S; Dong S; Mathis JM; Alahari SK
    Eur J Cancer; 2017 Feb; 72():1-11. PubMed ID: 27997852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
    Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
    Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.
    Medina PP; Nolde M; Slack FJ
    Nature; 2010 Sep; 467(7311):86-90. PubMed ID: 20693987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.